Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $5.9 million.

  • Revolution Medicines' Other Non-Current Liabilities rose 11418.75% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 11418.75%. This contributed to the annual value of $3.2 million for FY2024, which is 5102.89% down from last year.
  • Per Revolution Medicines' latest filing, its Other Non-Current Liabilities stood at $5.9 million for Q3 2025, which was up 11418.75% from $7.2 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Other Non-Current Liabilities peaked at $7.2 million during Q2 2025, and registered a low of $219000.0 during Q2 2022.
  • Its 5-year average for Other Non-Current Liabilities is $2.3 million, with a median of $1.4 million in 2021.
  • As far as peak fluctuations go, Revolution Medicines' Other Non-Current Liabilities plummeted by 6398.03% in 2022, and later skyrocketed by 206345.51% in 2023.
  • Over the past 5 years, Revolution Medicines' Other Non-Current Liabilities (Quarter) stood at $634000.0 in 2021, then plummeted by 52.52% to $301000.0 in 2022, then skyrocketed by 2063.46% to $6.5 million in 2023, then plummeted by 51.03% to $3.2 million in 2024, then skyrocketed by 85.58% to $5.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $5.9 million for Q3 2025, versus $7.2 million for Q2 2025 and $4.1 million for Q1 2025.